Funding Daily Summary
Funding Daily Summary: What Happened on November 5, 2026
Alethio raises $90 million to take blood-cancer antibody toward trials
T-Therapeutics raised $133 million for two T-cell engager programs targeting cancer and autoimmune diseases.
Today in brief
Alethio secured $90 million for ATX-011, an antibody targeting G6B, and other drug candidates.12 T-Therapeutics brought in $133 million to advance two experimental T-cell engager programs toward clinical testing.3
Alethio raises $90 million for blood-cancer programs
Alethio Therapeutics raised $90 million in a Series A co-led by Sofinnova Partners and RA Capital.1 Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford also participated.1
Alethio plans to take its G6B-targeting antibody ATX-011 through Phase 1/2a studies, aiming to prepare it for Phase 3.1 Alethio CEO Rohit Batta expects enrollment to start during the first six months of 2028, pending regulatory processes.1
The company plans to test ATX-011 first in essential thrombocythemia, a blood cancer in the myeloproliferative neoplasms group.1 Research using samples from more than 100 people with these disorders found G6B on abnormal stem cells, but not healthy blood stem cells.1
Experiments reported at the 2026 American Society of Hematology annual meeting found that ATX-011 did not activate human platelets or disrupt megakaryocyte maturation in a cell model.1 In two nonhuman primates, platelet counts fell 80% after 96 hours, then recovered as the antibody cleared.1 Modeling suggests dosing every three to four weeks might maintain normal platelet counts in patients, a possibility that still requires clinical testing.1
T-Therapeutics raises $133 million for two engager programs
T-Therapeutics raised $133 million in an oversubscribed Series B to advance two experimental T-cell engager programs for cancer and autoimmune diseases.3 Advent Life Sciences and British Business Bank jointly led the round. Johnson & Johnson Innovation, Samsara BioCapital, M-Ventures and Eli Lilly joined as new investors.3
The company aims to take both lead programs to clinical proof of concept.3 Its platform uses engineered mice to find human T-cell receptors, then incorporates them into bispecific molecules that bind a disease-associated target and CD3 on T cells.3
Chief executive Dominic Schmidt said the approach could make targets inside cells accessible to the drugs and potentially improve safety.3 T-Therapeutics appointed Kirsty Crame as chief development officer.3